Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2019
Price : $35 *
At a glance
- Drugs Grapiprant (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Arrys Therapeutics
- 18 Dec 2018 Planned initiation date changed from 31 Oct 2018 to 31 Dec 2018.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record